Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 8/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.70 |
| ▸ | CASP3 | P42574 | 2/20 | 0.70 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450954 | 0.84 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL7756394 | 0.84 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL6452396 | 0.81 | NOTUM (0.54) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL6449133 | 0.80 | KDM4E (0.66) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL6458875 | 0.80 | HSD17B10 (0.56) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL28628723 | 0.79 | L3MBTL1 (0.56) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL23451551 | 0.78 | NOTUM (0.54) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL21434730 | 0.78 | NOTUM (0.54) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL5541462 | 0.78 | HSD11B1 (0.55) | ALDH1A1HSD17B10NOTUMHSD11B1MAPK1 | |
| SCHEMBL6449524 | 0.77 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | RAB9A 2483/4885NPC1 59/4885SMN1; SMN2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.